Back to results
US 10,378,061 B2Granted
Biomarker for predicting effect of an anti-c-Met antibody
AssigneeSamsung Electronics Co., Ltd.
InventorsJongsuk Chung, Tae Jin Ahn, Dae-Soon Son, Eunjin Lee
Life of this patent
Estimating the term…
Abstract
A method of predicting an effect of an anti-c-Met antibody and/or selecting a subject for application of an anti-c-Met antibody including measuring a level of the biomarker in a biological sample, is provided.
Claims24
A method of selecting a subject for administration of an anti-c-Met antibody or antigen-binding fragment thereof, the method comprising:
- selecting for administration of an anti-c-Met antibody or antigen-binding antibody fragment a subject in which the expression level of one or more biomarkers including THSD7A is higher than the expression level of one or more reference markers including MATR3, or higher than the expression level of the one or more biomarkers in a reference sample on which the anti-c-Met antibody or antigen-binding fragment thereof has no effect or having a resistance to an anti-c-Met antibody or antigen-binding fragment thereof;
- wherein selecting the subject comprises:
- measuring the expression level of the one or more biomarkers in a biological cancer cell or tissue sample from a human subject;
- and
- comparing the expression level of the one or more biomarkers to the expression level of the one or more reference markers, or to the expression level of the one or more biomarkers in a reference sample;
- and
- administering the anti-c-Met antibody or antigen-binding fragment thereof to the selected subject,
- wherein the anti-c-Met antibody or antigen-binding fragment thereof specifically binds to an epitope which has 5 to 19 contiguous amino acids selected from the amino acid sequence of SEQ ID NO:
- 71, wherein the epitope comprises SEQ ID NO:
- 73;
- and
- the anti-c-Met antibody or antigen-binding fragment thereof comprises at least one heavy chain complementarity determining region (CDR) selected from a group consisting of (a) a CDR-H1 comprising SEQ ID NO:
- 4;
- (b) a CDR-H2 comprising SEQ ID NO:
- 5, SEQ ID NO:
- 2, or an amino acid sequence comprising 8-19 consecutive amino acids of SEQ ID NO:
- 2 including the 3rd to 10th positions of SEQ ID NO:
- 2;
- and (c) a CDR-H3 comprising SEQ ID NO:
- 6, SEQ ID NO:
- 85, or an amino acid sequence comprising 6-13 consecutive amino acids of SEQ ID NO:
- 85 including the 1st to 6th positions of SEQ ID NO:
- 85;
- and
- at least one light chain complementarity determining region selected from the group consisting of (a) a CDR-L1 comprising SEQ ID NO:
- 7, (b) a CDR-L2 comprising SEQ ID NO:
- 8, and (c) a CDR-L3comprising SEQ ID NO:
- 9, SEQ ID NO:
- 15, SEQ ID NO:
- 86, or an amino acid sequence comprising 9-17 consecutive amino acids of SEQ ID NO:
- 89 including the 1st to 9th positions of SEQ ID NO:
- 89;
- or a combination thereof.
30 more elements
A method of selecting and treating a human subject with a c-Met inhibitor, the method comprising:
- comparing the expression level of one or more biomarkers in a biological cancer cell or tissue sample from a human subject to the expression level of one or more reference markers, or to the expression level of the one or more biomarkers in a reference sample,
- wherein the one or more biomarkers includes THSD7A;
- the one or more reference markers includes MATR3;
- and the reference sample is a sample upon which the anti-c-Met antibody or antigen-binding fragment thereof has no effect or is resistant to treatment with an anti-c-Met antibody or antigen-binding fragment thereof;
- and
- selecting a subject with a THSD7A expression level that is higher than that of one or more reference markers or higher than the THSD7A expression level in the reference sample, and administering to the selected subject an anti-c-Met antibody or antigen-binding fragment thereof;
- wherein the anti-c-Met antibody or antigen-binding fragment thereof specifically binds to an epitope which has 5 to 19 contiguous amino acids selected from the amino acid sequence of SEQ ID NO:
- 71, wherein the epitope comprises SEQ ID NO:
- 73;
- and
- wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises at least one heavy chain complementarity determining region (CDR) selected from a group consisting of (a) a CDR-H1 comprising SEQ ID NO:
- 4;
- (b) a CDR-H2 comprising SEQ ID NO:
- 5, SEQ ID NO:
- 2, or an amino acid sequence comprising 8-19 consecutive amino acids of SEQ ID NO:
- 2 including the 3rd to 10th positions of SEQ ID NO:
- 2;
- and (c) a CDR-H3 comprising SEQ ID NO:
- 6, SEQ ID NO:
- 85, or an amino acid sequence comprising 6-13 consecutive amino acids of SEQ ID NO:
- 85 including the 1st to 6th positions of SEQ ID NO:
- 85;
- and
- at least one light chain complementarity determining region selected from the group consisting of (a) a CDR-L1 comprising SEQ ID NO:
- 7, (b) a CDR-L2comprising SEQ ID NO:
- 8, and (c) a CDR-L3 comprising SEQ ID NO:
- 9, SEQ ID NO:
- 15, SEQ ID NO:
- 86, or an amino acid sequence comprising 9-17 consecutive amino acids of SEQ ID NO:
- 89 including the 1st to 9th positions of SEQ ID NO:
- 89;
- or a combination thereof.
29 more elements
Dependencies are inferred from the claim text.